ZOM - Zomedica Pharmaceuticals Corp Stock Price, Fair Value and News

$0.120.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ZOM Price Action

Last 30 days

-7.7%

Last 90 days

-14.3%

Trailing 12 Months

-45.4%

ZOM RSI Chart

ZOM Valuation

Market Cap

117.6M

Price/Earnings (Trailing)

-3.45

Price/Sales (Trailing)

21.45

EV/EBITDA

-3.48

Price/Free Cashflow

-5.89

ZOM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ZOM Fundamentals

ZOM Revenue

Revenue (TTM)

5.5M

Rev. Growth (Yr)

10.24%

Rev. Growth (Qtr)

14.12%

ZOM Earnings

Earnings (TTM)

-34.0M

Earnings Growth (Yr)

-1.3K%

Earnings Growth (Qtr)

72.02%

ZOM Profitability

Operating Margin

65.45%

EBT Margin

-590.80%

Return on Equity

-16.79%

Return on Assets

-15.9%

Free Cashflow Yield

-16.96%

ZOM Investor Care

Diluted EPS (TTM)

-0.07

ZOM Alerts

4 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	20.7M	22.4M	24.0M	5.5M
2022	7.8M	11.5M	15.2M	18.9M
2021	1.1M	2.1M	3.1M	4.1M
2020	516.5K	0	274.7K	32.9K
2019	2.0M	0	1.9M	758.3K
2018	1.4M	0	1.3M	1.6M
2017	1.3M	0	1.3M	1.3M
2016	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Zomedica Pharmaceuticals Corp

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

CEO	Mr. Larry C. Heaton II
WEBSITE	zomedica.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	85

Zomedica Pharmaceuticals Corp Frequently Asked Questions

What is the ticker symbol for Zomedica Pharmaceuticals Corp? What does ZOM stand for in stocks?

ZOM is the stock ticker symbol of Zomedica Pharmaceuticals Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zomedica Pharmaceuticals Corp (ZOM)?

As of Fri Dec 20 2024, market cap of Zomedica Pharmaceuticals Corp is 117.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZOM stock?

You can check ZOM's fair value in chart for subscribers.

Is Zomedica Pharmaceuticals Corp a good stock to buy?

The fair value guage provides a quick view whether ZOM is over valued or under valued. Whether Zomedica Pharmaceuticals Corp is cheap or expensive depends on the assumptions which impact Zomedica Pharmaceuticals Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZOM.

What is Zomedica Pharmaceuticals Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ZOM's PE ratio (Price to Earnings) is -3.45 and Price to Sales (PS) ratio is 21.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZOM PE ratio will change depending on the future growth rate expectations of investors.